These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36779862)

  • 1. Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study.
    Pasnoor M; Bril V; Levine T; Trivedi J; Silvestri NJ; Phadnis M; Katzberg HD; Saperstein DS; Wolfe GI; Herbelin L; Higgs K; Heim AJ; Statland JM; Barohn RJ; Dimachkie MM
    Eur J Neurol; 2023 May; 30(5):1417-1424. PubMed ID: 36779862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
    Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
    PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.
    Eienbröker C; Seitz F; Spengler A; Kurz H; Seipelt M; Sommer N; Oertel WH; Timmesfeld N; Tackenberg B
    Muscle Nerve; 2014 Dec; 50(6):999-1004. PubMed ID: 24710856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.
    Beecher G; Anderson D; Siddiqi ZA
    Neurology; 2017 Sep; 89(11):1135-1141. PubMed ID: 28814461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis.
    Yasuda M; Uzawa A; Ozawa Y; Kojima Y; Onishi Y; Akamine H; Kuwabara S
    Scand J Immunol; 2022 Feb; 95(2):e13122. PubMed ID: 34796975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations.
    Karelis G; Balasa R; De Bleecker JL; Stuchevskaya T; Villa A; Van Damme P; Lagrange E; Heckmann JM; Nicolle M; Vilciu C; Bril V; Mondou E; Griffin R; Chen J; Henriquez W; Garcia B; Camprubi S; Ayguasanosa J
    Eur Neurol; 2019; 81(5-6):223-230. PubMed ID: 31655810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the use of immunoglobulins as treatment for myasthenia gravis.
    Alcantara M; Barnett C; Katzberg H; Bril V
    Expert Rev Clin Immunol; 2022 Jul; 18(7):703-715. PubMed ID: 35639497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
    Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
    Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
    J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
    Wolfe GI; Barohn RJ; Foster BM; Jackson CE; Kissel JT; Day JW; Thornton CA; Nations SP; Bryan WW; Amato AA; Freimer ML; Parry GJ;
    Muscle Nerve; 2002 Oct; 26(4):549-52. PubMed ID: 12362423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
    JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.
    Yin J; Zhao M; Xu X; Zhang M; Xu Z; Li Z; Qin X; Li Z; Zhao C; Zhou H; Ma Y; Cao W; Wang G; Lin Y; Zhang J; Zhang X; Cai H; Qian W; Wang Y; Zhang X; Liu G; Wang J; Qiu W; Min L; Li J; Deng H; Chu L; Zhang Y; Fang J
    Eur J Neurol; 2024 Aug; 31(8):e16322. PubMed ID: 38726639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka KV
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.